Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

NCT03317158 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma
Bladder Cancer

Interventions

DRUG: Durvalumab (Cohort 1-3)
RADIATION: External Beam Radiotherapy (EBRT)
BIOLOGICAL: Bacillus Calmette-Guérin (BCG)
DRUG: Gemcitabine
DRUG: Docetaxel
BIOLOGICAL: Tremelimumab
DRUG: Durvalumab (Cohort 4/5)
OTHER: To be determined

Sponsor

Noah Hahn, M.D.

Collaborators

[object Object]
[object Object]